MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Business Exposures
< Previous 1 2
...
24 25 26 27 28 29 30 31 32
...
99 100 Next >
News headline image
Ibogaine by David Dardashti Aligns with New Federal”Right to Try” Directives to Target the NeurologicalRoots of Childhood Trauma
Via AB Newswire
Exposures Product Safety
News headline image
Save This Psychedelic Stock Watchlist After Trump’s Latest Executive Order
Via Barchart.com
Topics Cannabis ETFs Government
Exposures Cannabis Political Product Safety
News headline image
Trump Sends Compass Pathways Stock Soaring as He Backs Psychedelics. Should You Buy CMPS Here?
Via Barchart.com
Topics Government
Exposures Political Product Safety
News headline image
AMATORUS WOUND GUARD Passes all Antimicrobial Efficacy Testing
Via Get News
Tickers AAPL
Exposures Product Safety
News headline image
Here's Why Agios Pharmaceuticals Crashed 23% Today ↗
Via The Motley Fool
Tickers AGIO NVO
Exposures Product Safety
News headline image
Why Compass Pathways Stock Rocketed 40% Today ↗
Via The Motley Fool
Topics Government
Tickers CMPS MMM
Exposures Political Product Safety
News headline image
What's Pushing Moderna Stock Higher Today? ↗
Via Benzinga
Tickers MRNA
Exposures Product Safety
PsychedelicNewsBreaks –  Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP) Supports Executive Order Advancing Psychedelic Therapies
Via Investor Brand Network
Tickers HELP
Exposures Product Safety
News headline image
Trump Just Fast-Tracked Psychedelic Treatments: 3 Under-the-Radar Stocks That Could Be About to Soar ↗
Via The Motley Fool
Topics Government
Tickers ATAI CMPS DFTX MMM
Exposures Political Product Safety
BioMedNewsBreaks — Lantern Pharma (NASDAQ: LTRN) Schedules FDA Type C Meeting For HARMONIC Trial Amendments
Via Investor Brand Network
Topics Artificial Intelligence
Tickers LTRN
Exposures Artificial Intelligence Product Safety
BioMedNewsBreaks — NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Supports Executive Order To Accelerate Psychedelic Drug Development
Via Investor Brand Network
Tickers BMWYY NRXP
Exposures Product Safety
News headline image
PharmaTher's Microneedle Patch Platforms Positioned to Benefit from Major U.S. Catalysts in Psychedelics and Peptides
Via Newsfile
Topics Government Intellectual Property
Tickers CSE:PHRM PHRRF
Exposures Intellectual Property Political Product Safety
News headline image
Baby Food Recalled After Jars Test Positive For Rat Poison ↗
Via Benzinga
Topics Product Recall
Exposures Legal Product Safety
News headline image
AMATORUS WOUND GUARD Passes all Antimicrobial Efficacy Testing
Via Press Release Distribution Service
Tickers AAPL
Exposures Product Safety
News headline image
Compass Pathways Cheers Trump Order To Accelerate Access To Psychedlic Drug Treatements: 'Recognizes Profound Urgency Of Mental Health Crisis' ↗
Via Benzinga
Topics Government
Exposures Political Product Safety
News headline image
IMMUNITYBIO DEADLINE FOR LEADERSHIP is May 26, 2026 in a Securities Fraud Lawsuit - Investors Encouraged to Contact Kaplan Fox
Via NewMediaWire
Topics Fraud Lawsuit
Tickers IBRX
Exposures Financial Legal Product Safety
News headline image
IMMUNITYBIO DEADLINE FOR LEADERSHIP is May 26, 2026 in a Securities Fraud Lawsuit - Investors Encouraged to Contact Kaplan Fox
Via TheNewswire.com
Topics Fraud Lawsuit
Tickers IBRX
Exposures Financial Legal Product Safety
News headline image
3 Catalysts That Could Send Teva Stock to $40 and Beyond ↗
Via The Motley Fool
Tickers AMGN EVR JEF JNJ REGN SPGI
Exposures Product Safety
News headline image
autoTECH Blackhawk Provides Reliable, Full-Service Car Maintenance in Danville
Via GetFeatured
Topics Economy Product Recall
Tickers F RACE
Exposures Economy Legal Product Safety
News headline image
The Psychedelic Revolution in Mental Healthcare ↗
Via The Motley Fool
Tickers ABBV CMPS
Exposures Product Safety
News headline image
Lifelike Tattoo Studio: Where Ink Becomes Identity in Houston
Via AB Newswire
Topics Product Recall
Exposures Legal Product Safety
News headline image
Bread Loaf’s CEO Mark Milutin Breaks Down FDA Peptide Shift and What It Means for Telehealth
Via AB Newswire
Exposures Product Safety
News headline image
Goldman Sachs' 2 Favorite Under-the-Radar Stocks ↗
Via Benzinga
Tickers GS
Exposures Product Safety
OEM Water Bottle Manufacturing Guide: A Complete Handbook for Brand Owners & Buyers
Via AB Newswire
Exposures Product Safety
News headline image
Deadline to Lead in Securities Class Action Against ImmunityBio, Inc. (NASDAQ: IBRX) is May 26, 2026 - Contact Kaplan Fox
Via TheNewswire.com
Topics Lawsuit
Tickers IBRX
Exposures Financial Legal Product Safety
News headline image
Deadline to Lead in Securities Class Action Against ImmunityBio, Inc. (NASDAQ: IBRX) is May 26, 2026 - Contact Kaplan Fox
Via NewMediaWire
Topics Lawsuit
Tickers IBRX
Exposures Financial Legal Product Safety
AINewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) Closes $10 Million Public Offering to Advance Cardiac Technology Commercialization
Via Investor Brand Network
Topics Artificial Intelligence Intellectual Property
Tickers BEAT
Exposures Artificial Intelligence Intellectual Property Product Safety
News headline image
$9.1 Billion Mesenchymal Stem Cell Market by 2031 to be Focused on by New Senior Scientific Advisor for KALA BIO, Inc. (Nasdaq: KALA)
Via Get News
Topics Artificial Intelligence Intellectual Property
Tickers KALA
Exposures Artificial Intelligence Intellectual Property Product Safety
News headline image
3 Under-the-Radar Healthcare Stocks Worth Adding to Your Watchlist ↗
Via The Motley Fool
Tickers EXEL JNJ KRYS LLY MDGL UNH
Exposures Product Safety
News headline image
Stock Market Today, April 16: Hims & Hers Health Jumps on FDA Review of Compounded Peptide Therapies ↗
Via The Motley Fool
Topics Stocks
Tickers BAC HIMS
Exposures Product Safety US Equities
< Previous 1 2
...
24 25 26 27 28 29 30 31 32
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story